Ken Griffin Clearside Biomedical, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 17,600 shares of CLSD stock, worth $19,184. This represents 0.0% of its overall portfolio holdings.

Number of Shares

17,600

Previous 8,500 107.06%

Holding current value

$19,184

Previous $13,000 69.23%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.08 - $1.58 $28,573 - $41,802	26,457 Added 37.7%	96,630 $125,000
Q1 2024 May 15, 2024	BUY	$1.2 - $2.02 $29,202 - $49,156	24,335 Added 53.09%	70,173 $107,000
Q4 2023 Feb 14, 2024	BUY	$0.68 - $1.18 $17,741 - $30,786	26,090 Added 132.11%	45,838 $53,000
Q3 2023 Nov 14, 2023	BUY	$0.82 - $1.27 $1,956 - $3,030	2,386 Added 13.74%	19,748 $17,000
Q2 2023 Aug 14, 2023	SELL	$0.97 - $1.48 $48,642 - $74,217	-50,147 Reduced 74.28%	17,362 $19,000
Q1 2023 May 15, 2023	BUY	$0.93 - $1.66 $60,383 - $107,780	64,928 Added 2515.61%	67,509 $70,000
Q4 2022 Feb 14, 2023	BUY	$1.0 - $1.5 $2,581 - $3,871	2,581 New	2,581 $2,000
Q2 2022 Aug 15, 2022	SELL	$1.3 - $2.49 $20,634 - $39,523	-15,873 Reduced 50.97%	15,266 $23,000
Q1 2022 May 16, 2022	SELL	$1.35 - $2.88 $10,183 - $21,723	-7,543 Reduced 19.5%	31,139 $71,000
Q4 2021 Feb 14, 2022	SELL	$2.72 - $5.72 $543,989 - $1.14 Million	-199,996 Reduced 83.79%	38,682 $106,000
Q3 2021 Nov 15, 2021	BUY	$4.83 - $7.2 $966,120 - $1.44 Million	200,025 Added 517.49%	238,678 $1.43 Million
Q2 2021 Aug 16, 2021	BUY	$2.32 - $5.38 $31,848 - $73,856	13,728 Added 55.08%	38,653 $188,000
Q1 2021 May 17, 2021	SELL	$2.24 - $4.25 $242,280 - $459,684	-108,161 Reduced 81.27%	24,925 $62,000
Q2 2020 Aug 14, 2020	BUY	$1.55 - $2.41 $104,204 - $162,021	67,229 Added 102.08%	133,086 $250,000
Q1 2020 May 15, 2020	BUY	$1.32 - $3.77 $10,916 - $31,177	8,270 Added 14.36%	65,857 $112,000
Q4 2019 Feb 14, 2020	BUY	$0.62 - $3.4 $2,093 - $11,478	3,376 Added 6.23%	57,587 $167,000
Q2 2019 Aug 14, 2019	BUY	$0.97 - $1.42 $3,968 - $5,809	4,091 Added 8.16%	54,211 $53,000
Q1 2019 May 15, 2019	SELL	$1.1 - $1.74 $15,286 - $24,180	-13,897 Reduced 21.71%	50,120 $0
Q4 2018 Feb 14, 2019	BUY	$1.0 - $6.12 $37,558 - $229,854	37,558 Added 141.95%	64,017 $68,000
Q3 2018 Nov 13, 2018	SELL	$6.03 - $11.24 $282,939 - $527,403	-46,922 Reduced 63.94%	26,459 $0
Q2 2018 Aug 10, 2018	SELL	$8.91 - $14.54 $933,937 - $1.52 Million	-104,819 Reduced 58.82%	73,381 $0
Q1 2018 May 11, 2018	BUY	$5.57 - $14.28 $992,574 - $2.54 Million	178,200 New	178,200 $1.91 Million

Others Institutions Holding CLSD

# of Institutions

Shares Held

13.5M

Call Options Held

17.6K

Put Options Held

100

View Full List

About Clearside Biomedical, Inc.

Ticker CLSD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,190,700
Market Cap $65.6M
Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...

More about CLSD

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account